- Home
- SEZL vs KRYS Comparison
SEZL vs KRYS Comparison
Compare SEZL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- KRYS
- Stock Information
- Founded
- SEZL 2016
- KRYS 2015
- Country
- SEZL United States
- KRYS United States
- Employees
- SEZL N/A
- KRYS N/A
- Industry
- SEZL Diversified Financial Services
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEZL Finance
- KRYS Health Care
- Exchange
- SEZL Nasdaq
- KRYS Nasdaq
- Market Cap
- SEZL 4.4B
- KRYS 3.8B
- IPO Year
- SEZL N/A
- KRYS 2017
- Fundamental
- Price
- SEZL $141.16
- KRYS $148.15
- Analyst Decision
- SEZL Strong Buy
- KRYS Strong Buy
- Analyst Count
- SEZL 3
- KRYS 10
- Target Price
- SEZL $108.28
- KRYS $205.50
- AVG Volume (30 Days)
- SEZL 1.1M
- KRYS 369.4K
- Earning Date
- SEZL 08-06-2025
- KRYS 08-04-2025
- Dividend Yield
- SEZL N/A
- KRYS N/A
- EPS Growth
- SEZL 677.39
- KRYS 109.01
- EPS
- SEZL 2.97
- KRYS 4.16
- Revenue
- SEZL $329,060,890.00
- KRYS $333,448,000.00
- Revenue This Year
- SEZL $66.19
- KRYS $44.05
- Revenue Next Year
- SEZL $25.26
- KRYS $46.15
- P/E Ratio
- SEZL $45.39
- KRYS $35.53
- Revenue Growth
- SEZL 91.69
- KRYS 247.53
- 52 Week Low
- SEZL $11.67
- KRYS $122.80
- 52 Week High
- SEZL $186.74
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- SEZL 47.03
- KRYS 59.74
- Support Level
- SEZL $161.44
- KRYS $139.20
- Resistance Level
- SEZL $186.74
- KRYS $151.48
- Average True Range (ATR)
- SEZL 14.01
- KRYS 5.30
- MACD
- SEZL -4.61
- KRYS 1.29
- Stochastic Oscillator
- SEZL 8.36
- KRYS 79.97
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.